Table 1:

Clinical characteristics and neuropsychological testing

SLE (n = 6)Healthy Controls (n = 5)P Value
Age (mean) (yr)38.0 ± 13.234.2 ± 10.5.619
Race.292
    Caucasian2 (33%)0
    Hispanic02 (40%)
    African American3 (50%)2 (40%)
    Asian1 (17%)1 (20%)
Smoking11.361
High serum DNRAb titer3 (50%)1 (20%).545
ANAM testinga
    Matching grids25.8 ± 9.240.4 ± 10.8.042
    Match to sample16.4 ± 5.935.7 ± 15.1.043
    Continuous processing65.6 ± 5.588.7 ± 14.0.018
Beck Depression Inventory4 ± 4.31.8 ± 3.0.362
State Trait Anxiety Inventory27.4 ± 5.925 ± 6.9.573
SLEDAI (mean)2.3 ± 1.5
SLICC DI (mean)0.5 ± 0.8
Disease duration (mean) (range, 1–33) (yr)13.3 ± 11.1
Medications
    Prednisone1 (17%) (5 mg QD)
    Immunosuppressionb2 (33%)
    Hydroxychloroquine5 (83%)

  • Note:—QD indicates once daily.

  • ↵a Automated Neuropsychological Assessment Metric: throughput scores that represent efficiency as a function of accuracy and time.

  • ↵b Both subjects were on mycophenolate mofetil; 1000 mg QD and 500 mg QD, respectively.